@article {10.3844/ajidsp.2020.44.54,
article_type = {journal},
title = {Direct Acting Anti-Viral Drugs Improve Health-Related Quality of Life in Patients' with Hepatitis C},
author = {Morad, Wesam and Othman, Warda and Elshimi, Esam and Shebl, Nashwa},
volume = {16},
number = {2},
year = {2020},
month = {Apr},
pages = {44-54},
doi = {10.3844/ajidsp.2020.44.54},
url = {https://thescipub.com/abstract/ajidsp.2020.44.54},
abstract = {Chronic hepatitis C Virus (HCV) causes significant decline in the Health Related Quality of Life (HRQL). Recently, direct Acting Anti-viral Drugs (DAA) have been endorsed as standard of care for treatment for HCV. To study the HRQL in patients with HCV and cirrhosis before and after DAA. Study design: Prospective cohort hospital based study. We included 500 patients with HCV and cirrhosis fulfilled all eligibility criteria for treatment and completed the survey of HRQL using (SF-36 and CLDQ questioners) before and after treatment. Patients were treated by combination of one of the following regimens: (a) Sofosbuvir (SOF) plus Daclatasvir (DAC) ± Ribavirin (RBV) in 2 divided doses or (b) SOF plus Simeprevir (SIM) ± RBV or c) SOF plus RBV. On treatment, 35.2% of the patients had a poor physical function and half of them had poor role-emotional, while 45.7% patients’ had excellent role-emotional, 49% noticed change in their mode, evaluation of HRQL before and after treatment through SF-36 and CLDQ showed an improvement in different domains. (p},
journal = {American Journal of Infectious Diseases},
publisher = {Science Publications}
}